Diego Brandao on Friday became the latest UFC fighter notified by the United States Anti-Doping Agency of a potential Anti-Doping Policy violation.
UFC officials on Friday released the following statement confirming Brandao’s possible drug test failure:
The UFC organization was notified today that the U.S. Anti-Doping Agency (USADA) informed Diego Brandao of a potential Anti-Doping Policy violation involving Carboxy-Tetrahydrocannabinol (“Carboxy-THC”) which is a metabolite of marijuana and/or hashish, above the decision limit of 180 ng/mL, stemming from an in-competition sample collected following his fight on January 2, 2016 in Las Vegas.
USADA, the independent administrator of the UFC Anti-Doping Policy, will handle the results management and appropriate adjudication of this case involving Brandao, as it relates to the UFC Anti-Doping Policy and future UFC participation. Because the Nevada State Athletic Commission was the regulatory body overseeing the fight in Las Vegas and has state licensing and jurisdiction over Brandao, USADA will work to ensure that the Commission has the necessary information to determine its proper judgment of Brandao’s potential anti-doping violation. Additional information will be provided at the appropriate time as the process moves forward.
The potential infraction stems from Brandao’s drug test related to his UFC 195 bout with Brian Ortega. Brandao lost the bout, so the bout result would not be affected, although Brandao would face sanctioning.